William Blair initiated coverage on Recro Pharma
$REPH
Biotechnology: Pharmaceutical Preparations
Health Care
William Blair initiated coverage of Recro Pharma with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/12/2021 | Outperform | William Blair |
With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ:SCTL) to Initiate Trading on March 22, 2022 SAN DIEGO and GAINESVILLE, Ga., March 21, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a r
Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2021. "At this time last yea
SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings. All construction and equipment installation related to this service expansion has been completed at the company's San Diego facility and final validation and commissioning activities are underway. The company expects that its new automated fill/finish line and lyophilization
According to data from Benzinga Pro, during Q4, Recro Pharma's (NASDAQ:REPH) reported sales totaled $22.30 million. Despite a 32.39% increase in earnings, the company posted a loss of $2.36 million. In Q3, Recro Pharma brought in $18.24 million in sales but lost $3.49 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Recro Pharma posted an R
Recro Pharma (NASDAQ:REPH) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Recro Pharma beat estimated earnings by 42.86%, reporting an EPS of $-0.04 versus an estimate of $-0.07. Revenue was up $12.39 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.0 which was followed by a 9.57% drop in the share price the next day. Here's a look at Recro Pharma's past performance: Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020 EPS Estimate -0.07 -0.11 -0.25 -0.25 EPS Actual -0.07 0.03 -
William Blair initiated coverage of Recro Pharma with a rating of Outperform
SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 fr
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Agreements Further Expanding Customer Base Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third q
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, November 9, 2021 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 fro
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
8-K - Societal CDMO, Inc. (0001588972) (Filer)
10-Q - Societal CDMO, Inc. (0001588972) (Filer)
8-K - Societal CDMO, Inc. (0001588972) (Filer)
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today. Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDM
SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)
SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)
SC 13G - Societal CDMO, Inc. (0001588972) (Subject)